China National Accord Medicines (SZSE:200028) Long-Term Capital Lease Obligation : HK$1,784 Mil (As of Mar. 2024)

View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines Long-Term Capital Lease Obligation?

China National Accord Medicines's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was HK$1,784 Mil.

China National Accord Medicines's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 (HK$1,471 Mil) to Dec. 2023 (HK$1,588 Mil) and increased from Dec. 2023 (HK$1,588 Mil) to Mar. 2024 (HK$1,784 Mil).

China National Accord Medicines's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (HK$1,684 Mil) to Dec. 2022 (HK$1,482 Mil) but then increased from Dec. 2022 (HK$1,482 Mil) to Dec. 2023 (HK$1,588 Mil).

China National Accord Medicines Long-Term Capital Lease Obligation Historical Data

The historical data trend for China National Accord Medicines's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Long-Term Capital Lease Obligation Chart

China National Accord Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1,344.71

1,544.68

1,684.17

1,482.33

1,587.94

China National Accord Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1,494.12	1,476.60	1,470.80	1,587.94	1,783.91

China National Accord Medicines (SZSE:200028) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

China National Accord Medicines Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

China National Accord Medicines (SZSE:200028) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:200028) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

000028:China

Address

No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029

Website

http://www.szaccord.com.cn

China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:200028) Headlines

No Headlines